Bukowski R - Search Results

1

Effect of renal cell carcinomas on the development of type 1 T-cell responses.

Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, Storkus WJ, Tannenbaum C, Novick A, Bukowski R, Finke J. Rayman P, et al. Among authors: bukowski r. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6360S-6S. doi: 10.1158/1078-0432.CCR-050011. Clin Cancer Res. 2004. PMID: 15448031

2

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R. Finke JH, et al. Among authors: bukowski r. Clin Cancer Res. 2008 Oct 15;14(20):6674-82. doi: 10.1158/1078-0432.CCR-07-5212. Clin Cancer Res. 2008. PMID: 18927310

3

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.

Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH. Ko JS, et al. Among authors: bukowski r. Clin Cancer Res. 2009 Mar 15;15(6):2148-57. doi: 10.1158/1078-0432.CCR-08-1332. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276286

4

The Bcl-2 transgene protects T cells from renal cell carcinoma-mediated apoptosis.

Molto L, Rayman P, Paszkiewicz-Kozik E, Thornton M, Reese L, Thomas JC, Das T, Kudo D, Bukowski R, Finke J, Tannenbaum C. Molto L, et al. Among authors: bukowski r. Clin Cancer Res. 2003 Sep 15;9(11):4060-8. Clin Cancer Res. 2003. PMID: 14519627

5

Degradation of NF-kappa B in T cells by gangliosides expressed on renal cell carcinomas.

Thornton MV, Kudo D, Rayman P, Horton C, Molto L, Cathcart MK, Ng C, Paszkiewicz-Kozik E, Bukowski R, Derweesh I, Tannenbaum CS, Finke JH. Thornton MV, et al. Among authors: bukowski r. J Immunol. 2004 Mar 15;172(6):3480-90. doi: 10.4049/jimmunol.172.6.3480. J Immunol. 2004. PMID: 15004148

6

GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction.

Biswas K, Richmond A, Rayman P, Biswas S, Thornton M, Sa G, Das T, Zhang R, Chahlavi A, Tannenbaum CS, Novick A, Bukowski R, Finke JH. Biswas K, et al. Among authors: bukowski r. Cancer Res. 2006 Jul 1;66(13):6816-25. doi: 10.1158/0008-5472.CAN-06-0250. Cancer Res. 2006. PMID: 16818659

7

TNF-alpha induction of GM2 expression on renal cell carcinomas promotes T cell dysfunction.

Raval G, Biswas S, Rayman P, Biswas K, Sa G, Ghosh S, Thornton M, Hilston C, Das T, Bukowski R, Finke J, Tannenbaum CS. Raval G, et al. Among authors: bukowski r. J Immunol. 2007 May 15;178(10):6642-52. doi: 10.4049/jimmunol.178.10.6642. J Immunol. 2007. PMID: 17475896

8

GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis.

Das T, Sa G, Hilston C, Kudo D, Rayman P, Biswas K, Molto L, Bukowski R, Rini B, Finke JH, Tannenbaum C. Das T, et al. Among authors: bukowski r. Cancer Res. 2008 Mar 15;68(6):2014-23. doi: 10.1158/0008-5472.CAN-07-6037. Cancer Res. 2008. PMID: 18339884

9

The role of inflammation in kidney cancer.

de Vivar Chevez AR, Finke J, Bukowski R. de Vivar Chevez AR, et al. Among authors: bukowski r. Adv Exp Med Biol. 2014;816:197-234. doi: 10.1007/978-3-0348-0837-8_9. Adv Exp Med Biol. 2014. PMID: 24818725 Review.

10

GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trial.

Hussein MA, Sandstrom K, Elson P, Finke J, McLain D, Rayman P, Rybicki LA, Bukowski RA. Hussein MA, et al. Among authors: bukowski ra. J Cancer Res Clin Oncol. 2001 Oct;127(10):619-24. doi: 10.1007/s004320100250. J Cancer Res Clin Oncol. 2001. PMID: 11599798

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

529 results

Search Page